View Financial HealthCumberland Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Cumberland Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回り-8.0%バイバック利回り総株主利回り-8.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesCumberland Pharmaceuticals Inc. to Report Q1, 2026 Results on May 05, 2026Apr 29Cumberland Pharmaceuticals Inc Announces Expanded Indication for Caldolor Ibuprofen InjectionApr 17Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 21, 2026Mar 10New major risk - Revenue and earnings growth Mar 09Full year 2025 earnings released: US$0.19 loss per share (vs US$0.46 loss in FY 2024) Mar 05New major risk - Revenue and earnings growth Mar 04Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2025 Results on Mar 03, 2026Feb 25Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% PoundingFeb 06Cumberland Pharmaceuticals Inc. Receives FDA Fast Track Designation for Its Ifetroban Duchenne Muscular Dystrophy ProgramFeb 04New minor risk - Share price stability Dec 16Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For GrowthDec 11Cumberland Pharmaceuticals Inc. Announces an Important Update Regarding its Caldolor®? (ibuprofen) InjectionDec 09Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?Nov 30Third quarter 2025 earnings released: US$0.13 loss per share (vs US$0.11 loss in 3Q 2024) Nov 06New major risk - Revenue and earnings growth Nov 05Cumberland Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 04, 2025Oct 29Cumberland Pharmaceuticals Inc. Adds Their Potent Antibativ®? to National Group Purchasing Agreement with Premier, IncOct 13Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S No Reason For ExcitementOct 08Cumberland Pharmaceuticals Announces Product Approval in MexicoOct 01Tabuk Pharmaceutical Manufacturing Company and Cumberland Pharmaceuticals Inc. Announces the Launch of Cumberland's Vibativ®? (Telavancin) Injection in Saudi ArabiaSep 30Second quarter 2025 earnings released Aug 06New major risk - Revenue and earnings growth Aug 06Insufficient new directors Aug 01Cumberland Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 05, 2025Jul 30New major risk - Share price stability Jun 30Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Not Doing Enough For Some Investors As Its Shares Slump 50%Jun 27Cumberland Pharmaceuticals Shares Phase 2 Fight Dmd Trial Results At the Parent Project Muscular Dystrophy Annual ConferenceJun 24Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?Jun 21Cumberland Pharmaceuticals Inc. Announces the Publication of Its Study InvestigatingCaldolor (Intravenous Ibuprofen) in Older PatientsMay 28Cumberland Pharmaceuticals Inc. Partners with Qureight to Advance Innovative Idiopathic Pulmonary Fibrosis Treatment ResearchMay 14Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%May 13First quarter 2025 earnings released: EPS: US$0.084 (vs US$0.14 loss in 1Q 2024) May 07Cumberland Pharmaceuticals Inc. to Report Q1, 2025 Results on May 06, 2025Apr 30Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 22, 2025Mar 11Full year 2024 earnings released: US$0.46 loss per share (vs US$0.44 loss in FY 2023) Mar 05Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%Mar 01Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2024 Results on Mar 04, 2025Feb 26Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?Feb 21Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals (Holdings) Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® (Telavancin) Injection in ChinaFeb 18Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 Fight DMD Trial in Duchenne Muscular Dystrophy Heart DiseaseFeb 04Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks JustifiedJan 15New major risk - Share price stability Dec 10Cumberland Pharmaceuticals Inc. Announces FDA Approves Supplemental New Drug Application (sNDA) for Its Acetadote (N-Acetylcysteine for Injection) ProductDec 10Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) Nov 10Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to KetorolacNov 06Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Nov 04Cumberland Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Nov 01Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023) Aug 07Cumberland Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024Jul 31First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023) May 08Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024May 01Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.Mar 21New minor risk - Share price stability Mar 15Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024Mar 14Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Mar 07Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022) Mar 06Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024Feb 28Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift SharesJan 09New minor risk - Shareholder dilution Dec 18Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022) Nov 10Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023Nov 01Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of AgeOct 11+ 1 more updateNew minor risk - Share price stability Oct 08Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/SOct 02Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Aug 10Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022) Aug 09Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023Aug 03Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric DrugsJun 27Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary FibrosisMay 24U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for CaldolorMay 16First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022) May 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?Mar 18Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021) Mar 08Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of DirectorsJan 19Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug AdministrationDec 13Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) Nov 19Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) Nov 10Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Nov 02Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022Nov 02Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021) Aug 11Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022Aug 03Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of DirectorsJul 21Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)Jul 20Cumberland Pharmaceuticals Inc. Announces Executive ChangesJun 05First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 12Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022May 04Insufficient new directors Apr 27Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?Apr 15Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle EastApr 01Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 10Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022Mar 03Now 22% undervalued Jan 14Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.Jan 06Checking In On Cumberland Pharmaceuticals Jan 04Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®Dec 01Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020) Nov 13Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?Nov 09Consensus forecasts updated Aug 17Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020) Aug 12決済の安定と成長配当データの取得安定した配当: CPIXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CPIXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Cumberland Pharmaceuticals 配当利回り対市場CPIX 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (CPIX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (CPIX) (最長3年)n/a注目すべき配当: CPIXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CPIXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CPIXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CPIXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/01 08:11終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cumberland Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Andrew D'SilvaB. Riley Securities, Inc.David WindleyJefferies LLCMarc GoodmanUBS Investment Bank1 その他のアナリストを表示
Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% PoundingFeb 06
Cumberland Pharmaceuticals Inc. Receives FDA Fast Track Designation for Its Ifetroban Duchenne Muscular Dystrophy ProgramFeb 04
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For GrowthDec 11
Cumberland Pharmaceuticals Inc. Announces an Important Update Regarding its Caldolor®? (ibuprofen) InjectionDec 09
Cumberland Pharmaceuticals Inc. Adds Their Potent Antibativ®? to National Group Purchasing Agreement with Premier, IncOct 13
Tabuk Pharmaceutical Manufacturing Company and Cumberland Pharmaceuticals Inc. Announces the Launch of Cumberland's Vibativ®? (Telavancin) Injection in Saudi ArabiaSep 30
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Not Doing Enough For Some Investors As Its Shares Slump 50%Jun 27
Cumberland Pharmaceuticals Shares Phase 2 Fight Dmd Trial Results At the Parent Project Muscular Dystrophy Annual ConferenceJun 24
Cumberland Pharmaceuticals Inc. Announces the Publication of Its Study InvestigatingCaldolor (Intravenous Ibuprofen) in Older PatientsMay 28
Cumberland Pharmaceuticals Inc. Partners with Qureight to Advance Innovative Idiopathic Pulmonary Fibrosis Treatment ResearchMay 14
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%May 13
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%Mar 01
Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals (Holdings) Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® (Telavancin) Injection in ChinaFeb 18
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 Fight DMD Trial in Duchenne Muscular Dystrophy Heart DiseaseFeb 04
Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks JustifiedJan 15
Cumberland Pharmaceuticals Inc. Announces FDA Approves Supplemental New Drug Application (sNDA) for Its Acetadote (N-Acetylcysteine for Injection) ProductDec 10
Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to KetorolacNov 06
Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023) Aug 07
Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.Mar 21
Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of AgeOct 11+ 1 more update
Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/SOct 02
Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric DrugsJun 27
Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary FibrosisMay 24
U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for CaldolorMay 16
Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of DirectorsJan 19
Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug AdministrationDec 13
Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021) Aug 11
Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle EastApr 01
Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.Jan 06